A slide set has been produced by Dr Matthew Burge, A/Prof Niall Tebbutt and Prof Tim Price, titled ‘Targeted therapy for metastatic colorectal cancer’. It has been designed as a resource for AGITG members who may have presentations to make at their institution or state-based meeting.Slide set: Targeted therapy for metastatic colorectal cancer
The aim of this slide set was to review the underlying molecular pathology of metastatic colorectal cancer (mCRC), in particular the clinical use of diagnostic, predictive and prognostic biomarkers. Quality evidence in this area varies significantly. The value and functionality of different biomarkers is not yet well understood.
These slides were developed following the Colorectal Cancer Consensus Meeting held by the AGITG and Adelaide Tumour Group in September 2018, coinciding with ESMO in Madrid. This meeting involved seven AGITG members noted below and three international colorectal cancer experts: Dr Daniel Haller, Professor Dirk Arnold, and Professor Marc Peeters.
The publication which resulted from the Consensus Meeting was: ‘Targeted therapy for metastatic colorectal cancer: Price TJ, Tang M, Gipps P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M, Shapiro J. Expert review of Anticcancer Therapy. 2018 Oct;18(10):991-1006.’
The slide resource covers:
- Introduction to biomarkers
- RAS mutations
- BRAF mutations
- Sidedness (primary tumour location)
- Deficient mismatch repair (dMMR)/microsatellite instability (MSI)
- Emerging biomarkers
- Biomarkers of chemotherapy sensitivity and toxicity
- Emerging technologies.
Roche provided funding support for the consensus meeting and this slide set.